Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew Rusinko is active.

Publication


Featured researches published by Andrew Rusinko.


Chemical Biology & Drug Design | 2016

Rapid Identification of Novel Inhibitors of the Human Aquaporin-1 Water Channel.

Rajkumar V. Patil; Shouxi Xu; Alfred N. Van Hoek; Andrew Rusinko; Zixia Feng; Jesse A. May; Mark Hellberg; Najam A. Sharif; M. B. Wax; Macarena Irigoyen; Grant J. Carr; Tom Brittain; Peter M. Brown; Damon Colbert; S. Sindhu Kumari; K. Varadaraj; Alok K. Mitra

Aquaporins (AQPs) are a family of membrane proteins that function as channels facilitating water transport in response to osmotic gradients. These play critical roles in several normal physiological and pathological states and are targets for drug discovery. Selective inhibition of the AQP1 water channel may provide a new approach for the treatment of several disorders including ocular hypertension/glaucoma, congestive heart failure, brain swelling associated with a stroke, corneal and macular edema, pulmonary edema, and otic disorders such as hearing loss and vertigo. We developed a high‐throughput assay to screen a library of compounds as potential AQP1 modulators by monitoring the fluorescence dequenching of entrapped calcein in a confluent layer of AQP1‐overexpressing CHO cells that were exposed to a hypotonic shock. Promising candidates were tested in a Xenopus oocyte‐swelling assay, which confirmed the identification of two lead classes of compounds belonging to aromatic sulfonamides and dihydrobenzofurans with IC50s in the low micromolar range. These selected compounds directly inhibited water transport in AQP1‐enriched stripped erythrocyte ghosts and in proteoliposomes reconstituted with purified AQP1. Validation of these lead compounds, by the three independent assays, establishes a set of attractive AQP1 blockers for developing novel, small‐molecule functional modulators of human AQP1.


Journal of Chemical Information and Modeling | 2013

Developing Descriptors To Predict Mechanical Properties of Nanotubes

Tammie L. Borders; Alexandre F. Fonseca; Hengji Zhang; Kyeongjae Cho; Andrew Rusinko

Descriptors and quantitative structure property relationships (QSPR) were investigated for mechanical property prediction of carbon nanotubes (CNTs). 78 molecular dynamics (MD) simulations were carried out, and 20 descriptors were calculated to build quantitative structure property relationships (QSPRs) for Youngs modulus and Poissons ratio in two separate analyses: vacancy only and vacancy plus methyl functionalization. In the first analysis, C(N2)/C(T) (number of non-sp2 hybridized carbons per the total carbons) and chiral angle were identified as critical descriptors for both Youngs modulus and Poissons ratio. Further analysis and literature findings indicate the effect of chiral angle is negligible at larger CNT radii for both properties. Raman spectroscopy can be used to measure C(N2)/C(T), providing a direct link between experimental and computational results. Poissons ratio approaches two different limiting values as CNT radii increases: 0.23-0.25 for chiral and armchair CNTs and 0.10 for zigzag CNTs (surface defects <3%). In the second analysis, the critical descriptors were C(N2)/C(T), chiral angle, and M(N)/C(T) (number of methyl groups per total carbons). These results imply new types of defects can be represented as a new descriptor in QSPR models. Finally, results are qualified and quantified against experimental data.


Journal of Medicinal Chemistry | 2003

A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.

Jesse A. May; Hwang-Hsing Chen; Andrew Rusinko; Vincent M. Lynch; Najam A. Sharif; Marsha A. McLaughlin


Archive | 2006

(indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions

Mark R. Hellberg; Najam A. Sharif; Jesse A. May; Andrew Rusinko; Hwamg Hsing Chen


Archive | 2007

6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS

Hwang-Hsing Chen; Andrew Rusinko; Mark R. Hellberg; Bryon S. Severns; Alan J. Henderson; Cheng Guo; Mark Hadden


Archive | 2005

Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Mark Hellberg; Andrew Rusinko; Alan J. Henderson; Cheng Guo; Mark Hadden; Hélène Decornez


Archive | 2007

6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of glaucoma and ocular hypertension

Hwang-Hsing Chen; Andrew Rusinko; Mark R. Hellberg; Bryon S. Severns; Alan J. Henderson; Cheng Guo; Mark Hadden


Archive | 2005

Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions

Mark R. Hellberg; Andrew Rusinko


Archive | 2010

3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES

Mark R. Hellberg; Steven T. Miller; Andrew Rusinko


Archive | 2006

5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases

Mark R. Hellberg; Steven T. Miller; Andrew Rusinko

Collaboration


Dive into the Andrew Rusinko's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cheng Guo

Albany Molecular Research

View shared research outputs
Top Co-Authors

Avatar

Mark Hadden

Albany Molecular Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge